GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Reshape Lifesciences Inc (STU:24O0) » Definitions » Cyclically Adjusted Price-to-FCF

Reshape Lifesciences (STU:24O0) Cyclically Adjusted Price-to-FCF : (As of Jun. 04, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Reshape Lifesciences Cyclically Adjusted Price-to-FCF?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted Price-to-FCF for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Reshape Lifesciences Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Reshape Lifesciences's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reshape Lifesciences Cyclically Adjusted Price-to-FCF Chart

Reshape Lifesciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Reshape Lifesciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Reshape Lifesciences's Cyclically Adjusted Price-to-FCF

For the Medical Devices subindustry, Reshape Lifesciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Reshape Lifesciences's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Reshape Lifesciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Reshape Lifesciences's Cyclically Adjusted Price-to-FCF falls into.



Reshape Lifesciences Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Reshape Lifesciences's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Reshape Lifesciences's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.552/131.7762*131.7762
=-0.552

Current CPI (Mar. 2024) = 131.7762.

Reshape Lifesciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -2.707 100.560 -3.547
201409 -2.477 100.428 -3.250
201412 -46.101 99.070 -61.321
201503 -53.732 99.621 -71.075
201506 -50.444 100.684 -66.022
201509 -38.676 100.392 -50.767
201512 -62.367 99.792 -82.356
201603 -3,102.500 100.470 -4,069.215
201606 -1,658.667 101.688 -2,149.444
201609 -375.273 101.861 -485.486
201612 -304.455 101.863 -393.863
201703 -35.802 102.862 -45.866
201706 -502.400 103.349 -640.590
201709 -364.154 104.136 -460.811
201712 -575.923 104.011 -729.662
201803 -62,991.667 105.290 -78,837.895
201806 -46,391.667 106.317 -57,500.956
201809 -784.400 106.507 -970.505
201812 -85.370 105.998 -106.132
201903 -5,044.000 107.251 -6,197.446
201906 -1,283.500 108.070 -1,565.055
201909 -777.200 108.329 -945.417
201912 -3.033 108.420 -3.686
202003 -21.438 108.902 -25.941
202006 -16.514 108.767 -20.007
202009 -10.494 109.815 -12.593
202012 -18.329 109.897 -21.978
202103 -22.114 111.754 -26.076
202106 -20.659 114.631 -23.749
202109 -19.608 115.734 -22.326
202112 -8.658 117.630 -9.699
202203 -18.073 121.301 -19.634
202206 -15.767 125.017 -16.619
202209 -11.882 125.227 -12.503
202212 -5.627 125.222 -5.922
202303 -2.772 127.348 -2.868
202306 -1.903 128.729 -1.948
202309 -0.754 129.860 -0.765
202312 -0.653 129.419 -0.665
202403 -0.552 131.776 -0.552

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Reshape Lifesciences  (STU:24O0) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Reshape Lifesciences Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Reshape Lifesciences's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Reshape Lifesciences (STU:24O0) Business Description

Traded in Other Exchanges
Address
1001 Calle Amanecer, San Clemente, CA, USA, 92673
Reshape Lifesciences Inc is a developer of minimally invasive medical devices to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.

Reshape Lifesciences (STU:24O0) Headlines

No Headlines